Quick Answer
MAXCYTE, INC. reported Total Revenue of $33.03 million for the year ending 2025.
- MAXCYTE, INC. showed a decrease of -14.5% in Total Revenue from 2024 to 2025.
- This data is from MAXCYTE, INC.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $5.15 million | Q3 2020: $6.76 million | Q1 2021: $6.49 million | Q2 2021: $7.11 million | Q3 2021: $10.14 million | Q1 2022: $11.59 million | Q2 2022: $9.61 million | Q3 2022: $10.64 million | Q1 2023: $8.58 million | Q2 2023: $9.04 million | Q3 2023: $8.00 million | Q1 2024: $11.34 million | Q2 2024: $10.43 million | Q3 2024: $8.16 million | Q1 2025: $10.39 million | Q2 2025: $8.51 million | Q3 2025: $6.83 million.
- Over the full 7 years of available data (2019 to 2025), MAXCYTE, INC.'s Total Revenue has grown by 52.8%.
- Historical annual values: Fiscal year 2025: $33.03 million | Fiscal year 2024: $38.63 million | Fiscal year 2023: $41.29 million | Fiscal year 2022: $44.26 million | Fiscal year 2021: $33.89 million | Fiscal year 2020: $26.17 million | Fiscal year 2019: $21.62 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: